Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age

A legfontosabb adatok

Ki végzi
GlaxoSmithKline
Hol
Austin, Bardstown, Bell Gardens, Boise, Charleston, Charlotte, Cortland, Corvallis, Dallas, Erie, Evansville, Falls Church, Hermitage, Houston, Lafayette, Lincoln, Los Angeles, Louisville, Nampa, Oakland, Orem, Phoenix, Pittsburgh, Plano, Richmond, Roseville, Sacramento, Salt Lake City, San Jose, Santa Clara, Sioux Falls, South Jordan, Syracuse, Victoria, Walnut Creek, Waxahachie, Wellington és Winston-Salem (Egyesült Államok)Mind a 38 helyszín megnézéseMég 1 másik országban, 3 helyszínen
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
945 fő vett részt
Kezdés
2020. aug. 25.
Befejezés
2023. nov. 21.
A vizsgálat típusa
Beavatkozással járó, 3 csoport
A vizsgált kezelések
  • Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ)
  • Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)
  • Placebo
A regiszteradat frissítve
2025. március 4.

Ki vehet részt

Életkor
16 év – 18 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol or/and participants' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol
  • Previous vaccination with 1 dose of quadrivalent meningococcal conjugate vaccine (MenACWY, Menveo or Menactra) at least 4 years prior to informed consent and assent as applicable
  • Written or /witnessed/thumb printed informed consent obtained from the participant/parent(s)/LAR(s) of the participant prior to performance of any study specific procedure
  • Written informed assent obtained from the participant (if applicable) along with informed consent from the participant's parent(s)/LAR(s) prior to performing any study specific procedure
  • A male or female between, and including, 16 and 18 years of age at the time of the first vaccination
  • Healthy participants as established by medical history and clinical examination before entering the study
  • Female participants of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as pre-menarche, current bilateral tubal ligation or occlusion, hysterectomy, bilateral ovariectomy or post-menopause
  • Female participants of childbearing potential may be enrolled in the study if the participant:; has practiced adequate contraception for 30 days prior to vaccination, and; has a negative pregnancy test on the day of vaccination, and; has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series

Ki nem vehet részt

  • Abnormal function of the immune system resulting from:; Clinical conditions; Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to study vaccination. This will mean prednisone ≥ 20 mg/day (for adult participants) or ≥ 0.5 mg/kg/day or 20 mg/day whichever is the maximum dose for pediatric participants, or equivalent. Inhaled and topical steroids are allowed; Administration of antineoplastic or immunomodulating agents or radiotherapy within 90 days prior to informed consent
  • Current or previous, confirmed, or suspected disease caused by N. meningitidis
  • Recurrent history or un-controlled neurological disorders or seizures; Prior/Concomitant therapy
  • Use of any investigational or non-registered product other than the study vaccine(s) during the period starting 30 days before the informed consent or planned use during the study period
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 180 days before the informed consent or planned administration during the study period
  • Previous vaccination with any group B meningococcal vaccine at any time prior to informed consent and assent as applicable
  • Previous vaccination with 2 doses of quadrivalent meningococcal conjugate vaccine (MenACWY, Menveo, Menactra or MenQuadfi); Prior/Concurrent clinical study experience
  • Participant concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product, will not be enrolled; Other exclusions
  • Medical conditions
  • Progressive, unstable, or uncontrolled clinical conditions
  • Clinical conditions representing a contraindication to intramuscular vaccination and blood draws
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the study
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines
  • History of any reaction or hypersensitivity likely to be exacerbated by any medicinal products or medical equipment whose use is foreseen in this study
  • History of neuroinflammatory or autoimmune condition
  • Known contact to an individual with any laboratory-confirmed N. meningitidis infection within 60 days, prior to enrolment
  • Child in care
  • Pregnant or lactating female
  • Female planning to become pregnant or planning to discontinue contraceptive precautions
  • Any study personnel or immediate dependents, family, or household member

Helyszínek itt: Egyesült Államok

Még 1 másik országban, 3 helyszínen

  • Austin, TexasHospital not named in the registry
  • Bardstown, KentuckyHospital not named in the registry
  • Bell Gardens, CaliforniaHospital not named in the registry
  • Boise, IdahoHospital not named in the registry
  • Charleston, South CarolinaHospital not named in the registry
  • Charlotte, North CarolinaHospital not named in the registry
  • Cortland, New YorkHospital not named in the registry
  • Corvallis, OregonHospital not named in the registry
  • Dallas, TexasHospital not named in the registry
  • Erie, PennsylvaniaHospital not named in the registry
  • Evansville, IndianaHospital not named in the registry
  • Falls Church, VirginiaHospital not named in the registry
  • Hermitage, TennesseeHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Lafayette, ColoradoHospital not named in the registry
  • Lincoln, NebraskaHospital not named in the registry
  • Los Angeles, CaliforniaHospital not named in the registry
  • Louisville, KentuckyHospital not named in the registry
  • Nampa, IdahoHospital not named in the registry
  • Oakland, CaliforniaHospital not named in the registry
  • Orem, UtahHospital not named in the registry
  • Phoenix, ArizonaHospital not named in the registry
  • Pittsburgh, PennsylvaniaHospital not named in the registry
  • Plano, TexasHospital not named in the registry
  • Richmond, VirginiaHospital not named in the registry
  • Roseville, CaliforniaHospital not named in the registry
  • Sacramento, CaliforniaHospital not named in the registry
  • Salt Lake City, UtahHospital not named in the registry
  • San Jose, CaliforniaHospital not named in the registry
  • Santa Clara, CaliforniaHospital not named in the registry
  • Sioux Falls, South DakotaHospital not named in the registry
  • South Jordan, UtahHospital not named in the registry
  • Syracuse, New YorkHospital not named in the registry
  • Victoria, TexasHospital not named in the registry
  • Walnut Creek, CaliforniaHospital not named in the registry
  • Waxahachie, TexasHospital not named in the registry
  • Wellington, FloridaHospital not named in the registry
  • Winston-Salem, North CarolinaHospital not named in the registry

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to evaluate the immunogenicity, safety and tolerability of rMenB+OMV NZ and MenACWY vaccines when concomitantly administered to healthy subjects 16-18 years of age.

A vizsgálat 3 csoportja

  • MenB+MenACWY GroupA vizsgált kezelés

    Participants received 1 dose of rMenB+OMV NZ vaccine administered concomitantly with 1 dose of MenACWY vaccine, as separate injections in each arm at Day 1, 1 dose of rMenB+OMV NZ vaccine at Day 61 and 1 dose of placebo at Day 91.

    Kezelés: Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid) és Placebo

  • MenB GroupA vizsgált kezelés

    Participants received 1 dose of rMenB+OMV NZ vaccine administered concomitantly with 1 dose of placebo, as separate injections in each arm at Day 1, 1 dose of rMenB+OMV NZ vaccine at Day 61 and 1 dose of MenACWY at Day 91.

    Kezelés: Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid) és Placebo

  • MenACWY GroupA vizsgált kezelés

    Participants received 1 dose of MenACWY vaccine administered concomitantly with 1 dose of placebo, as separate injections in each arm at Day1, 1 dose of rMenB+OMV NZ vaccine each administered at Day 61 and at Day 91.

    Kezelés: Meningococcal Group B Vaccine (GSK3536829A) (rMenB+OMV NZ), Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid) és Placebo

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase IIIB, Randomized, Observer-blind, Multicenter Study to Assess the Safety and Immunogenicity of GSK's Meningococcal Group B Vaccine When Administered Concomitantly With GSK's Meningococcal MenACWY Conjugate Vaccine to Healthy Subjects of 16-18 Years of Age
A regiszteradat frissítve
2025. március 4.